Selection dynamics of HCV genotype 3 resistance-associated substitutions under direct-acting antiviral therapy pressure

The chronic hepatitis C (CHC) treatment is currently based on the use of direct-acting antivirals (DAAs), and patients infected with hepatitis C virus genotype 3 (GT3) have emerged as a more difficult-to-cure population. The NS5A inhibitor daclatasvir (DCV) and sofosbuvir (SOF), an NS5B viral polyme...

Descripción completa

Detalles Bibliográficos
Autores principales: Rodrigues, João Paulo Vilela, Campos, Guilherme Rodrigues Fernandes, Bittar, Cintia, Martinelli, Ana de Lourdes Candolo, Campos, Marília Silveira de Almeida, Pereira, Leonardo Régis Leira, Rahal, Paula, Souza, Fernanda Fernandes
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9706524/
https://www.ncbi.nlm.nih.gov/pubmed/36410397
http://dx.doi.org/10.1016/j.bjid.2022.102717

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9706524/
https://www.ncbi.nlm.nih.gov/pubmed/36410397
http://dx.doi.org/10.1016/j.bjid.2022.102717

Ejemplares similares